DoW Vision, Translational Research Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The FY26 Vision Research Program Translational Research Award (TRA) is designed to support projects that bridge promising discoveries with practical applications such as new drugs, devices, or clinical practice guidelines, aiming to prepare these innovations for definitive clinical trials within or by the end of the award period. This award funds preclinical studies, clinical research, or pilot clinical trials but explicitly excludes full-scale clinical trials. Research proposals must align with designated FY26 VRP Focus Areas, ensuring relevance to the program's priorities. Key features of the TRA include a requirement that teams developing new drugs or devices possess regulatory approval expertise. The award offers a Partnering Principal Investigator Option, allowing for two co-Principle Investigators to lead the project collaboratively. Proposals undergo rigorous peer review based on criteria such as research rationale, strategy, impact, personnel qualifications, and plans for post-award transition. Additionally, programmatic review evaluates alignment with the TRA’s intent, contribution to the VRP portfolio, potential impact, and military health relevance. The program also reserves the option to share applications and reviews with the National Eye Institute for independent funding consideration. The award is administered by the Department of the Army under the Department of Defense, with support available via the eBRAP Help Desk.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Translational Research Award (TRA) supports translational research that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The TRA may be used to support preclinical studies, clinical research or a pilot clinical trial, but not a full-scale clinical trial. Research must align with at least one of the FY26 VRP Focus Areas.
Distinctive Features:
· If developing new drugs or device(s), the research team must include expertise in the regulatory approval process.
· The TRA includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI.
· Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, Personnel and Post-Award Transition Plan.
· Programmatic review criteria include adherence to the intent of the TRA, contribution to the VRP portfolio, relative impact and relevance to military health.
· The VRP may share FY26 TRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration.
